BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25010863)

  • 1. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
    Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
    Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
    Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
    Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.
    Wagner KD; El Maï M; Ladomery M; Belali T; Leccia N; Michiels JF; Wagner N
    Cells; 2019 Jan; 8(1):. PubMed ID: 30641926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
    Amin EM; Oltean S; Hua J; Gammons MV; Hamdollah-Zadeh M; Welsh GI; Cheung MK; Ni L; Kase S; Rennel ES; Symonds KE; Nowak DG; Royer-Pokora B; Saleem MA; Hagiwara M; Schumacher VA; Harper SJ; Hinton DR; Bates DO; Ladomery MR
    Cancer Cell; 2011 Dec; 20(6):768-80. PubMed ID: 22172722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.
    Nowak DG; Amin EM; Rennel ES; Hoareau-Aveilla C; Gammons M; Damodoran G; Hagiwara M; Harper SJ; Woolard J; Ladomery MR; Bates DO
    J Biol Chem; 2010 Feb; 285(8):5532-40. PubMed ID: 19906640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
    Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
    Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.
    Gammons MV; Fedorov O; Ivison D; Du C; Clark T; Hopkins C; Hagiwara M; Dick AD; Cox R; Harper SJ; Hancox JC; Knapp S; Bates DO
    Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6052-62. PubMed ID: 23887803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.
    Hatcher JM; Wu G; Zeng C; Zhu J; Meng F; Patel S; Wang W; Ficarro SB; Leggett AL; Powell CE; Marto JA; Zhang K; Ki Ngo JC; Fu XD; Zhang T; Gray NS
    Cell Chem Biol; 2018 Apr; 25(4):460-470.e6. PubMed ID: 29478907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma.
    Pritchard-Jones RO; Dunn DB; Qiu Y; Varey AH; Orlando A; Rigby H; Harper SJ; Bates DO
    Br J Cancer; 2007 Jul; 97(2):223-30. PubMed ID: 17595666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
    Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
    Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.
    Peiris-Pagès M; Harper SJ; Bates DO; Ramani P
    J Pathol; 2010 Oct; 222(2):138-47. PubMed ID: 20662003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
    Batson J; Toop HD; Redondo C; Babaei-Jadidi R; Chaikuad A; Wearmouth SF; Gibbons B; Allen C; Tallant C; Zhang J; Du C; Hancox JC; Hawtrey T; Da Rocha J; Griffith R; Knapp S; Bates DO; Morris JC
    ACS Chem Biol; 2017 Mar; 12(3):825-832. PubMed ID: 28135068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.
    Nowak DG; Woolard J; Amin EM; Konopatskaya O; Saleem MA; Churchill AJ; Ladomery MR; Harper SJ; Bates DO
    J Cell Sci; 2008 Oct; 121(Pt 20):3487-95. PubMed ID: 18843117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of IL-8 induced angiogenesis in uveal melanoma.
    Lattanzio L; Tonissi F; Torta I; Gianello L; Russi E; Milano G; Merlano M; Lo Nigro C
    Invest New Drugs; 2013 Oct; 31(5):1107-14. PubMed ID: 23912257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
    Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
    Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.
    Oltean S; Gammons M; Hulse R; Hamdollah-Zadeh M; Mavrou A; Donaldson L; Salmon AH; Harper SJ; Ladomery MR; Bates DO
    Biochem Soc Trans; 2012 Aug; 40(4):831-5. PubMed ID: 22817743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
    Wahid M; Pratoomthai B; Egbuniwe IU; Evans HR; Babaei-Jadidi R; Amartey JO; Erdelyi V; Yacqub-Usman K; Jackson AM; Morris JC; Patel PM; Bates DO
    Cancer Immunol Immunother; 2023 Dec; 72(12):4001-4014. PubMed ID: 37973660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.
    Merdzhanova G; Gout S; Keramidas M; Edmond V; Coll JL; Brambilla C; Brambilla E; Gazzeri S; Eymin B
    Oncogene; 2010 Sep; 29(39):5392-403. PubMed ID: 20639906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1.
    Belali T; Wodi C; Clark B; Cheung MK; Craig TJ; Wheway G; Wagner N; Wagner KD; Roberts S; Porazinski S; Ladomery M
    Biochim Biophys Acta Gene Regul Mech; 2020 Dec; 1863(12):194642. PubMed ID: 33017668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
    Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
    J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.